Close
  Indian J Med Microbiol
 

Figure 5: Cyst size quantification from toluidine blue stained sections analyzed at 8 weeks post SCI. Treatment with mAPP96-110 significantly reduced cyst size compared to SCI only (“no cells”) (a), while combined treatment with mAPP96-110 + hMSCs, APP96-110 + hMSCs and APP96-110 + nv-hMSCs significantly reduced cyst size compared to SCI only and APP96-110 (b). APP96-110 + hMSCs also significantly reduced cyst size compared to nv-hMSCs (c) (P < 0.05, two-way analysis of variance followed by Fisher’s least significant difference test). Data are expressed as the mean ±SD. Numbers of animals (n = 4–8) for each treatment group are shown in [Table 1]. APP96-110: Amyloid precursor protein peptide; hMSCs: human mesenchymal stromal cells; mAPP96-100: mutant amyloid precursor protein; nv: non-viable; SCI: spinal cord injury.

<b>Figure 5: Cyst size quantification from toluidine blue stained sections analyzed at 8 weeks post SCI.</b>
Treatment with mAPP96-110 significantly reduced cyst size compared to SCI only (“no cells”) (a), while combined treatment with mAPP96-110 + hMSCs, APP96-110 + hMSCs and APP96-110 + nv-hMSCs significantly reduced cyst size compared to SCI only and APP96-110 (b). APP96-110 + hMSCs also significantly reduced cyst size compared to nv-hMSCs (c) (<i>P</i> < 0.05, two-way analysis of variance followed by Fisher’s least significant difference test). Data are expressed as the mean ±SD. Numbers of animals (<i>n</i> = 4–8) for each treatment group are shown in [Table 1]. APP96-110: Amyloid precursor protein peptide; hMSCs: human mesenchymal stromal cells; mAPP96-100: mutant amyloid precursor protein; nv: non-viable; SCI: spinal cord injury.